Clinical Trials Logo

Cardiomyopathies clinical trials

View clinical trials related to Cardiomyopathies.

Filter by:

NCT ID: NCT03344159 Completed - Clinical trials for Pulmonary Arterial Hypertension

Spironolactone Therapy in Chronic Stable Right HF Trial

STAR-HF
Start date: April 1, 2018
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and mechanistic effects of spironolactone, an aldosterone receptor antagonist, on sympathetic nervous system activity and right heart function and remodeling in patients with chronic right heart failure.

NCT ID: NCT03340675 Recruiting - Clinical trials for Cardiomyopathy, Dilated

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

DMD
Start date: October 19, 2020
Phase: Phase 2
Study type: Interventional

Duchenne muscular dystrophy (DMD) is a devastating X-linked disease which leads to loss of ambulation between ages 7 and 13, respiratory failure and cardiomyopathy (CM) at any age, and inevitably premature death of affected young men in their late twenties. DMD is the most common fatal genetic disorder diagnosed in childhood. It affects approximately 1 in every 3,500 live male births across all races and cultures, and results in 20,000 new cases each year worldwide.Significant advances in respiratory care have unmasked CM as the leading cause of death. As there are yet no specific cardiac treatments to extend life, the current study aims to address this unmet medical need using a new therapeutic strategy for patients with DMD. Funding Source - FDA OOPD

NCT ID: NCT03335332 Completed - Clinical trials for Hypertrophic Cardiomyopathy

High Intensity Exercise for Increasing Fitness in Patients With Hypertrophic Cardiomyopathy

Start date: January 31, 2018
Phase: N/A
Study type: Interventional

Although current clinical guidelines stipulate that patients with hypertrophic cardiomyopathy should not partake in high intensity exercise (HIE) or competitive sport due to safety concerns, there is no clear evidence to support this notion. In fact, two exercise training interventions in this population indicates that regular moderate to vigorous intensity exercise is efficacious for improving exercise capacity and cardiorespiratory fitness, and does not increase arrhythmia burden or adverse events. Moreover, moderate intensity exercise and HIE training significantly increases cardiorespiratory fitness in patients with cardiac disease. Such improvements are associated with substantial reductions in cardiovascular mortality and might outweigh the risk of adverse events in patients with hypertrophic cardiomyopathy (HCM). Having a genetic cardiomyopathy does not grant immunity against lifestyle related cardiometabolic diseases and inactivity is rife in HCM patients likely due to misinformation/education. It is therefore paramount to further explore the benefits of regular moderate intensity exercise and HIE in patients with HCM for proper therapeutic management of the condition.

NCT ID: NCT03327623 Recruiting - Clinical trials for Hypertrophic Cardiomyopathy

Sleep Apnea and Hypertrophic Cardiomyopathy (HCM)

Start date: November 13, 2017
Phase:
Study type: Observational

The investigators are trying to find out how common sleep apnea is in hypertrophic cardiomyopathy. The purpose of this study is to see if sleep apnea is common in hypertrophic cardiomyopathy and if its presence is associated with changes in the functioning of the body. The investigators want to determine if sleep apnea is associated with electrical disorders of the heart in patients with hypertrophic cardiomyopathy.

NCT ID: NCT03317964 Recruiting - Cardiomyopathies Clinical Trials

Genetic Basis of Pacing-induced Cardiomyopathy

Start date: October 16, 2017
Phase:
Study type: Observational

The purpose of this study is to collect a saliva sample from patients with a pacemaker to study genes involved in cardiomyopathy, a condition where the heart muscle is abnormal.

NCT ID: NCT03304847 Recruiting - Cardiomyopathy Clinical Trials

Arrhythmogenic Substrate in Primary Cardiomyopathies and/or Channellopathies

Start date: January 24, 2018
Phase: N/A
Study type: Interventional

This study assesses the value of arrhythmogenic substrate identification and elimination by catheter ablation to prevent recurrent ventricular arrhythmias and sudden cardiac death in a series of selected patients with primary cardiomyopathy and/or channellopaties with ICD implantation.

NCT ID: NCT03299790 Completed - Type2 Diabetes Clinical Trials

Effect of High-intensity Interval Training on Cardiac Function and Regulation of Glycemic Control in Diabetic Cardiomyopathy

Start date: October 6, 2017
Phase: N/A
Study type: Interventional

According to data of the International Diabetes Federation (IDF), diabetes in general affects approximately 415 million people worldwide and this number is still increasing. Cardiovascular diseases, one of the major complications of diabetes, are the leading cause of mortality and morbidity in the diabetic population. One of the cardiovascular complications is diabetic cardiomyopathy, in which structural and functional changes occur in the heart impairing cardiac function. Exercise training has already proven the benefits on glycemic control in diabetes. This is also the case for the effects on cardiac function. However, as results are conflicting, it remains unclear which elements of exercise training should be focused on. For instance, high-intensity interval training (HIIT) is gaining interest as positive effects are already shown on glycemic control. Therefore, the potential of HIIT to improve cardiac function in diabetes should be investigated. Further on, the effects of exercise training on cardiac function are mainly investigated during rest by the use of transthoracic echocardiography. Therefore, as data are lacking, it remains unclear how the diabetic heart functions during exercise. The aim of the present study is to investigate the effects of different training modalities (e.g. HIIT) on heart function in diabetes both during rest and during exercise itself. Therefore, cardiac function will be evaluated by the use transthoracic (exercise) echocardiography. This will be combined by the evaluation of several biochemical parameters. The results will provide more insight in the pathology of diabetic cardiomyopathy as well as the potential of exercise training for this cardiovascular complication. Eventually, this research will contribute to the optimization of exercise programs for patients with diabetes.

NCT ID: NCT03299569 Recruiting - Clinical trials for Myocardial Infarction

Establishing the Incidence of Tako-tsubo Cardiomyopathy in Scotland

STARR
Start date: July 29, 2016
Phase:
Study type: Observational [Patient Registry]

Acute stress-induced (Takotsubo cardiomyopathy) presents like a heart attack and is triggered by intense emotional or physical stress. Although coronary arteries are unobstructed, it has been suggested that the risk of death is similar to a myocardial infarction. The purpose of the STARR study is to identify all cases of Takotsubo in Scotland since 2010 and assess its epidemiology and outcomes.

NCT ID: NCT03294707 Completed - Clinical trials for Amyloid Cardiomyopathy, Transthyretin-Related

Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10

Start date: September 11, 2017
Phase: Phase 1
Study type: Interventional

This is a single center, prospective, randomized, placebo-controlled study of AG10 in healthy adult subjects

NCT ID: NCT03293381 Enrolling by invitation - Clinical trials for Non-ischemic Cardiomyopathy

Electrogram-Guided Myocardial Advanced Phenotyping

eMAP
Start date: November 30, 2018
Phase:
Study type: Observational

Fluoroscopy guided EMB and EAM guided EMB on all patients meeting existing guidelines for biopsy.